- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00939653
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)
T2007-002 A Phase II Study of Clofarabine With Etoposide and Cyclophosphamide in Relapsed/Refractory AML (IND 104,650)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90027
- Childrens Hospital Los Angeles
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami Cancer Center
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Children's Memorial
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404-4597
- Childrens Hospital & Clinics of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: patients must be ≥ 1 and ≤ 21 years of age at the of study entry.
Diagnosis:
- Patients must have a diagnosis of first or second relapse or refractory acute myelogenous leukemia (AML) according to WHO classification with ≥ 5% blasts in the bone marrow, with or without extramedullary disease.
- Patients may have CNS 1 or CNS 2 disease but not CNS 3.
- Performance Level: Karnofsky > 50% for patients > 16 years of age and Lansky > 50% for patients ≤ 16 years of age.
Prior Therapy:
- Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
- Patient has not received more than 2 previous induction attempts. (Frontline therapy is included in this count).
- Patients must have adequate venous access.
- At least 1 year must have elapsed since hematopoietic stem cell transplant (HSCT) and patients must not have active GVHD.
Reproductive Function
- Female patients of childbearing potential must have a negative serum pregnancy test confirmed within 2 weeks prior to enrollment.
- Female patients with infants must agree not to breastfeed their infants while on this study.
- Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of 6 months after study treatment.
- Renal and Hepatic Function:
Patient must have adequate renal and hepatic functions as indicated by the following laboratory values:
Patients must have a normal calculated creatinine clearance.
- Pediatric Population (age <18): Calculated creatinine clearance ≥ 90 ml/min/1.73m2 as calculated by the Schwartz formula for estimated glomerular filtration rate (GFR) where GFR (ml/min/1.73 m2) = k*Height (cm)/serum creatinine (mg/dl). k is a proportionality constant which varies with age and is a function of urinary creatinine excretion per unit of body size; 0.45 up to 12 months of age; 0.55 children and adolescent girls; and 0.70 adolescent boys.
- Adult Population (age ≥18): Serum creatinine ≤1.0 mg/dL; if serum creatinine >1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be >60 mL/min/1.73 m2 as calculated by the Modification of Diet in Renal Disease equation where Predicted GFR (ml/min/1.73 m2) = 186 x (Serum Creatinine)-1.154 x (age in years)-0.023 x (0.742 if patient is female) x (1.212 if patient is black.
- Total bilirubin <1.5 x ULN for age and conjugated/direct serum bilirubin ≤ ULN for age if total bilirubin is elevated.
- Aspartate transaminase (AST)/alanine transaminase (ALT) ≤ 2.5 × ULN.
- Alkaline phosphatase ≤ 2.5 × ULN.
Exclusion Criteria:
- Patients with Down Syndrome.
- Prior treatment with Clofarabine.
- Previous history of veno-occlusive disease (VOD) or findings consistent with a diagnosis of VOD, defined as: conjugated serum bilirubin > 1.4 mg/dL AND unexplained weight gain greater than 10% of baseline weight or ascites AND hepatomegaly or right upper quadrant pain without another explanation, OR reversal of portal vein flow on ultrasound, OR pathological confirmation of VOD on liver biopsy.
- Patients who have a history of cirrhosis of the liver or who are positive for hepatitis B core antibody (anti-HBc) or have a positive test for hepatitis C antibody (anti-HCV).
- Patient has received TBI.
- If it has been less than 1 year since the patient had a HSCT.
Infection Criteria
- Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
- Positive blood culture within 48 hours of study registration.
- Patient required supplemental oxygen or vasopressors within 48 hours of study (Oxygen after anesthesia for procedures is ok).
- Patient is receiving or plans to receive concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.
- Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before planned drug initiation with the exception of hydroxyurea or intrathecal therapy given with the diagnostic lumbar puncture.
- Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment.
- Pregnant or lactating patients.
- Any significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.
Have had a diagnosis of another malignancy, unless the patient has been disease-free for at least 3 years following the completion of curative intent therapy with the following exceptions:
- Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed.
- Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (PSA) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm - Clofarabine with Chemo
All patients receive the same treatment regimen consisting of clofarabine, etoposide, cyclophosphamide, cytarabine, and filgrastim.
Up to 4 courses of therapy may be given.
|
40 mg/m2/day IV over 2 hours (given at hours 0 to 2) on days 1 through 5.
Other Names:
100 mg/m2/day IV over 2 hours (given at hours 2 to 4) on days 1 through 5.
Other Names:
440 mg/m2/day IV as a 30-60 minute infusion (given at hours 4 to 5) on days 1 through 5.
Other Names:
Administered in Courses 1 and 2 only.
5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is > 1000 x 2 days.
Other Names:
Given intrathecally on day 1 at the dose defined by age below: 30 mg for patients age 1-1.99 50 mg for patients age 2-2.99 70 mg for patients >3 years of age
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Achievement of Complete Remission (CR) at Reinduction
Time Frame: Between Days 22-36 or on Day 43 and weekly thereafter if peripheral counts haven't recovered
|
Disease response assessed after chemotherapy from bone marrow aspirates/biopsies and complete blood count.
|
Between Days 22-36 or on Day 43 and weekly thereafter if peripheral counts haven't recovered
|
Death
Time Frame: From the first dose of study therapy until 30 days after last therapy dose
|
Number of participants who died.
|
From the first dose of study therapy until 30 days after last therapy dose
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Paul Gaynon, MD, Children's Hospital Los Angeles
- Study Chair: Nobuko Hijiya, MD, Ann & Robert H Lurie Children's Hospital of Chicago
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Adjuvants, Immunologic
- Cyclophosphamide
- Etoposide
- Clofarabine
- Lenograstim
- Cytarabine
Other Study ID Numbers
- T2007-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed Acute Myelogenous Leukemia
-
Masonic Cancer Center, University of MinnesotaCompletedRelapsed Acute Myelogenous Leukemia | Refractory Acute Myelogenous LeukemiaUnited States
-
Dana-Farber Cancer InstituteKaryopharm Therapeutics Inc; William Lawrence and Blanche Hughes FoundationActive, not recruitingRelapsed Acute Lymphoblastic Leukemia (ALL) | Refractory Acute Lymphoblastic Leukemia (ALL) | Relapsed Acute Myelogenous Leukemia (AML) | Refractory Acute Myelogenous Leukemia (AML) | Relapsed Mixed Lineage Leukemia | Refractory Mixed Lineage Leukemia | Relapsed Biphenotypic Leukemia | Refractory... and other conditionsUnited States
-
Therapeutic Advances in Childhood Leukemia ConsortiumTerminatedRelapsed Acute Lymphoblastic Leukemia | Relapsed Acute Myelogenous LeukemiaUnited States
-
Aptose Biosciences Inc.TerminatedAcute Myelogenous Leukemia | Acute Myelogenous Leukemia in Relapse | Acute Myelogenous Leukemia, Relapsed, Adult | Acute Myelogenous Leukemia, Adult | High Risk MyelodysplasiaUnited States
-
Genzyme, a Sanofi CompanyCompletedAcute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Relapsed LeukemiaUnited States
-
Dana-Farber Cancer InstituteBoston Children's Hospital; Brigham and Women's HospitalCompletedMyelogenous Leukemia, AcuteUnited States
-
Cooperative Study Group A for HematologyCompletedACUTE MYELOGENOUS LEUKEMIAKorea, Republic of
-
Wake Forest University Health SciencesCompleted
-
Wake Forest University Health SciencesCompleted
-
Hoffmann-La RocheCompletedNeoplasms, Myelogenous Leukemia, AcuteUnited States, Canada
Clinical Trials on Clofarabine
-
University of TexasCompletedAcute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia
-
Indiana University School of MedicineGenzyme, a Sanofi CompanyCompletedHematologic MalignanciesUnited States
-
Genzyme, a Sanofi CompanyTerminatedMyelodysplastic SyndromesUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); The Cleveland Clinic; University of RochesterCompletedLymphoma | Leukemia | Small Intestine CancerUnited States
-
Genzyme, a Sanofi CompanyCompletedAcute Myelogenous LeukemiaUnited States
-
Omar MianRecruitingAdenocarcinoma | Carcinoma | Metastatic CancerUnited States
-
Genzyme, a Sanofi CompanyCompletedLeukemia, Lymphoblastic, Acute, PediatricUnited States
-
Indiana University School of MedicineGenzyme, a Sanofi CompanyCompletedNon Hodgkin's LymphomaUnited States
-
Genzyme, a Sanofi CompanyCompletedSolid Tumors | Leukemia, Myelocytic, Acute, Pediatric | Leukemia, Lymphocytic, Acute, Pediatric | Leukemia, Lymphocytic, Acute, Adult | Leukemia, Myelocytic, Acute, Adult | Myelodysplastic Syndromes, AdultUnited States
-
Genzyme, a Sanofi CompanyCompletedAcute Myeloid Leukemia | Acute Myelogenous LeukemiaUnited States